Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get AVIR alerts

About Janet Hammond

The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,767,234 for Janet Hammond in fiscal 2025, including a base salary of $590,892. Disclosed compensation is on record for 6 fiscal years. Janet Hammond has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Atea Pharmaceuticals, Inc. on November 9, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.

Janet Hammond on recent calls

“Bemrusesvir is a once-daily fixed-dose regimen. Benifospivir is a highly potent HCV nucleotide, and rusesvir is a highly The potent NS5A inhibitor. Together, they have been administered to thousands of individuals with generally favorable safety and tolerability.”
Other, Third Quarter 2026 Financial Results Conference Call ·
“From a regulatory perspective, as JT mentioned, we're aiming to file the NDA mid-next year, and we're already actively preparing for that regulatory submission with drafting documents, drafting the label, and discussing things with physicians.”
Other, Morgan Stanley 24th Annual Global Healthcare Conference ·
“Following EASL, ATAR held a hepatitis C key opinion leader event that featured a panel of six leaders in hepatology, gastroenterology, infectious disease, and HCV research from the U.S., Canada, and Europe.”
Other, Atea Pharmaceuticals, Inc. Q2 FY2025 Earnings Call ·
“Turning to slide 20, COVID-19 continues to evolve, and as Jean-Pierre mentioned earlier, we're now experiencing a summer wave across the US, Europe, and other global locations, which is largely being driven by the new KP and LB.1 variants.”
CFO, Atea Pharmaceuticals, Inc. Q2 FY2024 Earnings Call ·
“To reiterate Jean-Pierre's earlier remarks, COVID-19 continues to be an established pathogen of concern with significant unmet need despite the availability of approved vaccines and antiviral treatment options.”
CFO, Atea Pharmaceuticals, Inc. Q1 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Atea Pharmaceuticals, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Atea Pharmaceuticals, Inc. (AVIR) $590,892 $1,767,234
2024 Atea Pharmaceuticals, Inc. (AVIR) $573,682 $2,159,031
2023 Atea Pharmaceuticals, Inc. (AVIR) $556,973 $2,107,297
2022 Atea Pharmaceuticals, Inc. (AVIR) $530,450 $2,112,151
2021 Atea Pharmaceuticals, Inc. (AVIR) $515,000 $9,007,023
2020 Atea Pharmaceuticals, Inc. (AVIR) $197,115 $4,030,318

Recent activity